Oncological research is experiencing a phase of extraordinary vitality and constant evolution, thanks to the evidence emerged in recent years on gene-environment interactions and the great impulse to precision medicine. A therapeutic approach that takes into account the genetic variability of the individual, but also the influence of lifestyle on health and the risk of developing specific diseases, with the aim of identifying more and more personalized preventive and therapeutic strategies.

Istituto Gentili focuses its activity on the development of innovative oncology drugs, exploiting consolidated partnership capacities. The company's mission is to offer patients with severe neoplasms and unmet medical needs highly effective and tested drugs.